Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 23, 2026, 1:14 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 165 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Conversion Clear all
Completed Phase 4 Interventional

Preventing ICU Subsyndromal Delirium Conversion to Delirium With Haloperidol

NCT01174290
View directory record Official record
Conditions
Subsyndromal Delirium
Interventions
Haloperidol decanoate, Placebo
Drug
Lead sponsor
Northeastern University
Other
Eligibility
18 Years to 84 Years
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety of Intranasal MSP-2017 (Etripamil) for the Conversion of PSVT to Sinus Rhythm

NCT02296190
View directory record Official record
Conditions
Paroxysmal Supraventricular Tachycardia (PSVT)
Interventions
Etripamil, Placebo
Drug
Lead sponsor
Milestone Pharmaceuticals Inc.
Other
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
26
States / cities
Phoenix, Arizona • Sacramento, California • Littleton, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2020 · Synced Oct 23, 2026, 1:14 PM EDT
Recruiting Not applicable Interventional

Bump the Lump - Intervention for the Treatment of Globus Pharyngeus

NCT06762444
View directory record Official record
Conditions
Globus Pharyngeus
Interventions
Speech-language pathologist (SLP) protocol
Behavioral
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Terminated Not applicable Interventional

Body Composition Optimization Intervention RCT

NCT05993169
View directory record Official record
Conditions
Obesity, Morbid
Interventions
Body Composition optimization visits
Other
Lead sponsor
Jacob M. Elkins
Other
Eligibility
18 Years to 99 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Dec 27, 2023 · Synced Oct 23, 2026, 1:14 PM EDT
Completed No phase listed Observational Results available

Neuroimaging Biomarkers of Prognosis in Motor Functional Neurological Disorders

NCT03398070
View directory record Official record
Conditions
Conversion Disorder
Interventions
Standard of Care
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 29, 2023 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Long-term Dietary Nitrate Consumption to Plasma Nitrite Conversion

NCT05380167
View directory record Official record
Conditions
Cardiovascular Diseases in Old Age
Interventions
BRJ Nitrate, BRJ Placebo
Dietary Supplement
Lead sponsor
Wake Forest University
Other
Eligibility
40 Years to 80 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2022 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 1 Interventional

A Conversion Study of Immediate Release (IR) and Modified Release (MR) Forms of Topiramate (TPM)

NCT01114854
View directory record Official record
Conditions
Epilepsy
Interventions
Topiramate IR, Topiramate ER
Drug
Lead sponsor
Supernus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
9
States / cities
Phoenix, Arizona • Little Rock, Arkansas • National City, California + 6 more
Source: ClinicalTrials.gov public record
Updated May 18, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Neuroimaging Biomarker for Seizures

NCT03441867
View directory record Official record
Conditions
Seizure Disorder, Seizure Disorder, Post Traumatic, Traumatic Brain Injury, Non-Epileptic Seizure, Conversion Disorder, Magnetic Resonance Imaging, Head Injury, Epilepsy
Interventions
Cognitive Behavioral Therapy for Seizures, Standard Medical Care
Behavioral · Other
Lead sponsor
Providence VA Medical Center
Federal
Eligibility
18 Years to 60 Years
Enrollment
224 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2022
U.S. locations
3
States / cities
Birmingham, Alabama • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Oct 23, 2026, 1:14 PM EDT
Terminated Phase 4 Interventional Results available

Conversion to Embeda With Rescue Trial

NCT01179191
View directory record Official record
Conditions
Chronic Disease, Pain
Interventions
morphine sulfate and naltrexone hydrochloride (EMBEDA)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
21 Years and older
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
166
States / cities
Adamsville, Alabama • Birmingham, Alabama • Huntsville, Alabama + 144 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Safety and Efficacy Study of Everolimus to Treat BK Virus Infection in Kidney Transplant Recipients

NCT01624948
View directory record Official record
Conditions
BK Virus Infection
Interventions
Everolimus, Mycophenolic acid dose reduction
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Not applicable Interventional

Testing a Conversion Factor for a More Rapidly Acting Insulin in an Automated Insulin Delivery System Among Adolescents With T1D

NCT06948760
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Control-IQ insulin pump with Lyumjev insulin, Control-IQ insulin pump with Humalog or Novolog
Device
Lead sponsor
Mark D. DeBoer, MD, MSc., MCR
Other
Eligibility
12 Years to 22 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Sep 8, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Active, not recruiting No phase listed Observational

Long-term Outcomes of Complex Conversion Total Hip Arthroplasty

NCT06533020
View directory record Official record
Conditions
Arthroplasty Complications
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 9, 2025 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Liver Transplant Patients

NCT00608244
View directory record Official record
Conditions
Liver Failure
Interventions
LCP Tacro, Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Aug 28, 2015 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Atorvastatin (Lipitor) Therapy in Patients With Clinically Isolated Syndrome (CIS) at Risk for Multiple Sclerosis

NCT00094172
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Atorvastatin, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
82 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
13
States / cities
Phoenix, Arizona • Los Angeles, California • San Francisco, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 28, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Not listed Phase 2 Interventional

Early Conversion From CNI to Belatacept in Renal Transplant Recipients With Delayed and Slow Graft Function

NCT01837043
View directory record Official record
Conditions
Delayed Graft Function, Kidney Transplant
Interventions
Belatacept, Calcineurin Inhibitor
Drug
Lead sponsor
Nair, Vinay, D.O.
Individual
Eligibility
18 Years to 70 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

Pharmacokinetics of LCP-Tacro in Stable Kidney Transplant Patients

NCT00496483
View directory record Official record
Conditions
Renal Failure
Interventions
LCP Tacro (tacrolimus), Prograf
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
2
States / cities
Cincinnati, Ohio • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 23, 2015 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Provitamin A Absorption and Conversion With Avocados

NCT01432210
View directory record Official record
Conditions
Healthy
Interventions
Post-prandial Feeding Study
Other
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 2 Interventional Results available

IAI Versus Sham as Prophylaxis Against Conversion to Neovascular AMD

NCT02462889
View directory record Official record
Conditions
Age-Related Macular Degeneration
Interventions
Intravitreal aflibercept injection, Placebo
Drug
Lead sponsor
Jeffrey S Heier
Other
Eligibility
Not listed
Enrollment
128 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Beverly Hills, California • Boston, Massachusetts • Edison, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2025 · Synced Oct 23, 2026, 1:14 PM EDT
Completed No phase listed Observational

Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

NCT03413722
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Tacrolimus, Everolimus
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years to 85 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 22, 2024 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 4 Interventional Results available

Evaluation of Calcineurin-inhibitor Reduction With Conversion at 2 Months to Everolimus/Reduced Tacrolimus in Renal Transplant Recipients Following Campath® Induction

NCT01935128
View directory record Official record
Conditions
Renal Transplant
Interventions
Arm 1 Everolimus/Reduced dose tacrolimus
Drug
Lead sponsor
University of Toledo Health Science Campus
Other
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2022 · Synced Oct 23, 2026, 1:14 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

A Study to Assess the Safety and Efficacy of Oral Armour Thyroid Compared to Synthetic T4 for the Treatment of Primary Hypothyroidism in Adult Participants

NCT06345339
View directory record Official record
Conditions
Hypothyroidism
Interventions
Armour Thyroid, Levothyroxine
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 75 Years
Enrollment
2,701 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
134
States / cities
Birmingham, Alabama • Bonita, California • Burbank, California + 110 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 23, 2026, 1:14 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety Study to Evaluate Vadadustat for the Correction or Maintenance Treatment of Anemia in Participants With Incident Dialysis-dependent Chronic Kidney Disease (DD-CKD)

NCT02865850
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
369 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
54
States / cities
Huntsville, Alabama • Mesa, Arizona • Anaheim, California + 45 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 23, 2026, 1:14 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Switching Medications From Intravenous to Oral

NCT03666520
View directory record Official record
Conditions
Physician's Role, Administration, Oral
Interventions
Clinical Decision Support prompted to the clinician to convert drug.
Other
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
921 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 8, 2019 · Synced Oct 23, 2026, 1:14 PM EDT
Recruiting Not applicable Interventional

Pilot Neurobehavioral Therapy for Functional Neurological Disorder

NCT06873698
View directory record Official record
Conditions
Functional Neurological Disorder
Interventions
Neuro-behavioral Therapy, Standard Medical Care (SMC)
Behavioral · Other
Lead sponsor
Rhode Island Hospital
Other
Eligibility
18 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 23, 2026, 1:14 PM EDT